Journal of Antimicrobial Chemotherapy · 1993 · 51 citations · 0 references
MedicinePediatricsPharmacotherapyOtologyPediatric OtolaryngologyPediatric PharmacotherapyOtitis MediaPediatric Antibiotic TherapyPediatric Antimicrobial TherapyPediatric Ear DisordersPediatric OtologyAcute Otitis Media ManagementAcute Otitis Media TreatmentEar Infections In Children
An open randomized trial was conducted in 159 children (aged 1 to 8 years) with acute otitis media to compare the clinical efficacy of azithromycin ( n = 105) and co-amoxiclav ( n = 54). Azithromycin (10 mg/kg/day) was administered as a single dose for three days and co-amoxiclav was given tid for ten days at a dosage according to the manufacturer's instructions for the country. Of 103 evaluable azithromycin patients on day 3 to 5 after the start of therapy, 31 (30%) were considered cured, 67 (65%) improved and five (5%) failed compared with eight (15%) cured, 45 (83%) improved and one (2%) failed among the 54 evaluable co-amoxiclav treated patients. There was a higher number of azithromycin patients with complete resolution of symptoms at this first visit ( P = 0.056). By day 10 to 12, clinical equivalence between the two treatment groups was observed with clinical cure in 86 (88%), improvement in 11 (11%) and failure in one (1%) of the 98 azithromycin patients, and in the 54 patients treated with co-amoxiclav, clinical cure was observed in 45 (83%), and improvement in nine (17%) patients. Both drugs were well tolerated and treatment related side-effects were reported in 8/105 (8%) azithromycin and 2/54 (4%) co-amoxiclav patients. In the azithromycin treatment group, these were predominantly mild to moderate gastrointestinal effects, whilst in the co-amoxiclav treatment group, both reports were of mild erythematous rash. One patient from each treatment group was withdrawn due to side-effects (azithromycin — diarrhoea and vomiting; co-amoxiclav — erythematous pruritic rash). Laboratory test abnormalities (predominantly decreased neuprophil count) were observed in 9/100 (9%) and 8/52 (15%) of patients in the azithromycin and co-amoxiclav groups, respectively. In conclusion, three-day, once-daily azithromycin therapy was found to be clinically equivalent to ten-day tid co-amoxiclav in otitis media in children. Furthermore, there was a trend towards a faster resolution of clinical symptoms with azithromycin.